Patents
Literature
3 results about "Fluvastatin Sodium" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
The sodium salt of a synthetic lipid-lowering agent with potential antineoplastic activity. Fluvastatin competitively inhibits hepatic 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. This agent lowers plasma cholesterol and lipoprotein levels, and modulates immune responses through the suppression of MHC II (major histocompatibility complex II) on interferon gamma-stimulated, antigen-presenting cells such as human vascular endothelial cells. Through the inhibition of mevalonate synthesis, statins, like fluvastatin, have been shown to inhibit the production of dolichol, geranylpyrophosphate (GPP) and farnesylpyrophosphate (FPP) and the isoprenylation of the intracellular G-proteins Ras and Rho, which may result in antiangiogenic, apoptotic, and antimetastatic effects in susceptible tumor cell populations.
A preparation method of fluvastatin sodium impurity F
The application discloses a preparation method of fluvastatin sodium impurity F, and specifically comprises the following steps: firstly, fluvastatin alcohol ketone is dissolved in an acid solvent to perform a dehydration reaction, then a reduction reaction is performed under the condition of a reducing catalyst, and finally, a hydrolysis reaction is performed with sodium hydroxide to obtain fluvastatin sodium impurity F. The application provides a preparation method of fluvastatin sodium impurity F, which is low in cost, simple in operation, high in yield and easy in process purification. The method uses fluvastatin sodium intermediate (fluvastatin alcohol ketone) as a raw material, the raw material is easy to obtain, and the impurity F can be prepared through only three chemical reactions, and each step does not need a complicated refining process. The fluvastatin sodium impurity F prepared by the application is high in yield and high in purity, and can be used as a standard or control product for quality control and production monitoring of fluvastatin sodium.
Owner:LAKERSPHARMA CO LTD
Fluvastatin Sodium Sustained Release Tablets and Preparation Method
ActiveCN119185228BOrganic active ingredientsMetabolism disorderPlastic packagingProlonged-release tablet
The present invention relates to the field of pharmaceutical technology, and discloses fluvastatin sodium sustained-release tablets and a preparation method. The weight ratio of the raw materials of the sustained-release tablets is as follows: 25-29 parts of cellulose derivatives; 5-9 parts of polyethylene substances; 20-24 parts of fluvastatin sodium; 20-25 parts of fillers; 1-3 parts of binders; 1-1.2 parts of disintegrants; 2-3 parts of lubricants. Weigh all the raw material components according to the raw material ratio, and mix the above components evenly in sequence. Granulate the powder mixed in the previous step by dry granulation to form uniform granules. Use a fluidized bed coating device to evenly coat the coating material on the surface of the granules to form a moisture-proof and sustained-release functional coating layer. Put the coated granules into a tablet press and press them into the shape and thickness of the tablets preset by the manufacturer, and control the pressure and temperature at the same time to prepare the sustained-release tablets. Conduct quality inspection on the prepared fluvastatin sodium sustained-release tablets. Finally, perform aluminum-plastic packaging on the qualified sustained-release tablets after quality inspection and store them in a cool and dry place.
Owner:HANGZHOU HONGYOU PHARM TECH CO LTD
